Results 201 to 210 of about 173,723 (245)
Some of the next articles are maybe not open access.
Rasagiline for motor complications in Parkinson's disease
Lancet, The, 2005Carl E Clarke
exaly +3 more sources
Motor complications of Parkinson's disease
Neurological Sciences, 2003Long-term treatment with levodopa in Parkinson's disease results in the development of motor complications, including drug failure, reduced duration of antiparkinsonian action (wearing off phenomenon), sudden shifts between under-treated and over-treated states (on-off phenomenon), freezing and involuntary movements such as levodopainduced dyskinesia ...
MARTIGNONI, EMILIA SILVANA +3 more
openaire +3 more sources
Motor Paralysis Complicating Herpes Zoster
Dermatologica, 2009Two patients in whom transient paralysis complicated cutaneous herpes zoster infection are described. The major features of this condition are reviewed.
E, Nord +3 more
openaire +2 more sources
Levodopa motor complications in Parkinson's disease
Trends in Neurosciences, 2000Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60,000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year.
J A, Obeso, C W, Olanow, J G, Nutt
openaire +2 more sources
Opioids and motor complications in Parkinson's disease
Trends in Pharmacological Sciences, 2006The long-term treatment of Parkinson's disease with L-dopa is often associated with the appearance of involuntary movements called L-dopa-induced dyskinesias. These debilitating side-effects are thought to result from an aberrant form of plasticity triggered by a combination of factors related to dopamine denervation and repeated L-dopa administration.
Pershia, Samadi +2 more
openaire +2 more sources
Pharmacogenetics and levodopa induced motor complications
International Journal of Neuroscience, 2018L-dopa remains the most effective symptomatic therapy for Parkinson's disease (PD) but unfortunately, its chronic use is often associated with motor complications. This review highlights the importance of pharmacogenetics in an individualised PD therapeutic approach.review of the literature was done.PD patients show remarkable heterogeneity in their ...
Kallirhoe, Kalinderi +2 more
openaire +2 more sources
MOTOR COMPLICATIONS OF HERPES ZOSTER
Age and Ageing, 1979Motor involvement is uncommon in herpes zoster. Of 14 subjects observed over an arbitrary period of five years, nine had flaccid limb paralyses, involving the upper limb in eight patients. Recovery was not always complete and occurred over a period of nine weeks to four years.
openaire +2 more sources
New dopaminergic therapies for PD motor complications
Neuropharmacology, 2022Motor complications, characterized by "off" periods - when anti-parkinsonian medications are ineffective - and dyskinesia, are the hallmark of advanced Parkinson's disease (PD). While levodopa is the gold standard PD medication in terms of efficacy, its short duration of effect coupled with progressive loss of dopaminergic neurons leads to motor ...
Danielle, Larson, Tanya, Simuni
openaire +2 more sources
Relevance of motor complications in Parkinson’s disease
Neurology, 2002Although patients with Parkinson's disease usually respond to dopaminergic therapy with a smooth, continued effect when medication is first initiated, many patients eventually develop a fluctuating response along with involuntary movements (dyskinesias).
openaire +2 more sources
Management of motor complications in Parkinson’s disease
Neurology, 2004Motor fluctuations in Parkinson's disease (PD) typically develop after 4-6 years of therapy, and affect approximately half of all patients. The wearing-off effect is the most common type, and "delayed-on," "no-on," and "on-off" effects, as well as dyskinesias, may also develop as the disease progresses.
openaire +2 more sources